Tengion, Inc. is an American development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina. Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform. Tengion declared Chapter 7 bankruptcy in December 2014, and liquidated its assets. In March 2015 its assets, including tissue engineering samples, were bought back by its creditors and former executives in March 2015. The purchase was expedited. The new owners then formed Winston-Salem based RegenMedTX. Wikipedia